THOMAS GIORDANO to Imatinib Mesylate
This is a "connection" page, showing publications THOMAS GIORDANO has written about Imatinib Mesylate.
Connection Strength
0.022
-
A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010 Sep; 20(9):975-80.
Score: 0.022
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.